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Abstract
Objectives: The purpose of this study was to analyze how anti-infectious periodontal treatment affects C reactive 
protein (CRP) values in patients with type 1 diabetes, and correlate baseline CRP levels with periodontal disease 
severity. 
Study Design: A cohort of fifty three subjects with type 1 diabetes and moderate to severe periodontitis were 
recruited. Periodontal parameters were measured, and blood samples were obtained to evaluate high-sensitivity 
C-reactive protein (hs-CRP). Group 1 was treated with scaling, root planning, and systemic administration of 
doxycycline. Group 2 received only scaling and root planning.
Results: Hs-CRP was reduced after periodontal treatment in group 1 (-0.22 mg/l) and 2 (-0.21 mg/l ) but this 
reduction was not statistically significant, even in the patients with the best response to periodontal treatment. 
However, significant correlation appeared between hs-CRP and mean probing pocket depth (PPD) (p=0, 01) and 
mean clinical attachment level (CAL) (p=0,03). 
Conclusions: Non-surgical periodontal treatment couldn’t reduce hs-CRP values, however, it was found an asso-
ciation between advanced periodontitis and elevated blood hs-CRP levels in patients with type 1 diabetes. It can 
be speculated that periodontal disease increases production of pro-inflammatory mediators in patients with type 
1 diabetes, but other producing sources of these pro-inflammatory substances may exist.
Key words: Periodontal disease, periodontitis, diabetes mellitus type 1, periodontal therapy, C reactive protein. 
Llambés F, Silvestre FJ, Hernández-Mijares A, Guiha R, Bautista D, Ca-
ffesse R . Efect of periodontal disease and non surgical periodontal treat-
ment on C-reactive protein. Evaluation of type 1 diabetic patients. Med 
Oral Patol Oral Cir Bucal. 2012 Jul 1;17 (4):e562-8.   
 http://www.medicinaoral.com/medoralfree01/v17i4/medoralv17i4p562.pdf
Article Number: 17793          http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
doi:10.4317/medoral.17793
http://dx.doi.org/doi:10.4317/medoral.17793
Med Oral Patol Oral Cir Bucal. 2012 Jul 1;17 (4):e562-8.                                                                                                                                                        CRP in type 1 diabetes and periodontitis
e563
Introduction
Periodontal disease is a chronic infectious disease, trig-
gered by the bacterial biofilm of dental plaque, which 
produced an inflammatory destruction of soft and hard 
tooth supporting structures (1). It is a high prevalence 
disease and studies have shown that about 10% of the 
adult population and about 30% of individuals over the 
age of 50 years suffer from severe periodontitis. This 
prevalence should be even higher in patients with dia-
betes because clinical and epidemiological studies have 
reported that patients with a long history of diabetes 
seem to have more periodontal tissue breakdown than 
age  matched, non-diabetic controls (2,3). Severity and 
progression of the periodontitis is also higher in indi-
viduals with diabetes (4).
The host responds to the periodontal infections through 
the immune system which produce inflammatory me-
diators after the interaction with the bacteria plaque. 
Although periodontitis is a chronic infection, acute-
phase elements are also involved in this immunological 
response and confirm that in periodontitis a systemic 
inflammation is present (5). This acute-phase reactants 
have pro-inflammatory properties; they help to neutral-
ize invasive pathogens and stimulate repair and regen-
eration of tissues. C-reactive protein (CRP), plasmino-
gen-activator 1(PAI-1), and fibrinogen are acute-phase 
reactants, but among all of them, CRP in particular has 
been focus of attention because elevated levels consti-
tute a risk factor for cardiovascular disease (CVD) (6,7). 
Nowadays, CRP is considered as a biomarker of sys-
temic inflammation.
Diabetes Mellitus is a multifactorial metabolic disease. 
Recent evidence suggests that chronic subclinical in-
flammation plays an important role in the development 
of the disease (8). On the other hand, elevated circulat-
ing levels of subclinical inflammatory markers, such as 
C-reactive protein (CRP) and interleukin-6 (IL-6) are 
reported to be significant risk indicators not only for the 
development of cardiovascular disease, but also for the 
development or progression of diabetes (9). Several re-
ports have demonstrated elevated serum CRP levels in 
patients with periodontitis compared with healthy con-
trols (10,11) and  some clinical studies have suggested 
that successful non-surgical periodontal treatment can 
reduce CRP levels in systemically healthy subjects (12). 
However these results are inconclusive (13,14) and only 
a few articles in the literature analyze the relationship 
between CRP and periodontal disease in patients with 
diabetes and none of them are done with type 1 diabetic 
individuals (15-17).
The purpose of this study was to analyze how anti-
infectious periodontal treatment affects CRP values in 
patients with type 1 diabetes and if baseline CRP levels 
are related to periodontal disease severity. Our results 
will help to understand the role of plasma inflammatory 
mediators in subjects with diabetes as well as their rela-
tionship with the periodontal disease and its treatment. 
We have to keep in mind that high CRP values could 
increase the risk for the development and progression of 
diabetes, and if they would be reduced, a better control 
of diabetes and periodontal disease could be achieved. 
Material and Methods
Study population
This randomized controlled clinical pilot study was 
conducted at Dr. Peset University Hospital in Valen-
cia (Spain).  Study protocol was approved by Dr. Pe-
set Hospital Clinic Research Committee, and partici-
pants signed an approved consent form to participate 
in the study. Fifty three subjects with type 1 diabetes 
and moderate to severe periodontitis (25 females and 
28 males) ranging in age from 19 to 60 (mean 35 ± 9 
years) were recruited from the endocrinology division 
for this single-blind study. Patients with type 1 diabe-
tes were diagnosed according to the criteria published 
by the American Diabetes Association in 1997 (18), and 
they were treated by insulin, diet, and physical exercise 
recommendations.
Participants had diabetes for more than 1 year, and none 
of them had other major illnesses or severe diabetic 
complications. Patients had not taken antibiotics for at 
least 3 months prior to baseline and did not have any ac-
tive infection. A panoramic radiograph was taken to as-
sure that neither extensive caries nor periapical lesions 
were present. Eligible subjects had 14 or more natural 
teeth, of which at least five had a site with probing pock-
et depth (PPD) ≥ 5 mm and clinical attachment level 
(CAL) ≥ 3 mm. From this point, subjects with moderate 
to severe periodontal disease were included. They had 
not had periodontal treatment or professional cleaning 
of the teeth for at least 1 year prior to the study. Preg-
nant and breastfeeding women were excluded. Twenty 
patients (38%) had good diabetic control (HbA1c < 7%), 
12 individuals (22%) had moderate control (HbA1c be-
tween 7% and 8%), and 40% of the sample (21 diabetic 
individuals) had poor metabolic control (HbA1c > 8%) 
according to the American Diabetes Association crite-
ria (19). Most of the patients selected were nonsmok-
ers (32 patients), some smoked less than 15 cigarettes 
per day (11 patients), and the rest were heavy smokers 
consuming 15 or more cigarettes per day (10 patients) 
(Table 1).
Laboratory and periodontal examination
Fasting venous blood was collected in vacuum tubes 
early in the morning, and high-sensitivity C-reactive 
protein (hs-CRP) was measured. Plasma hs-CRP levels 
were assessed using a kit with specific high-sensitivity 
methodology in a spectrophotometer according to the 
manufacturer’s instructions. The test samples were 
treated with a specific antibody to human CRP in a suit-
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able buffer. The turbidity induced by the formation of 
immune complexes was measured at 546 nm, and the 
values were automatically calculated from a known 
standard. The lower detection limit for the assay was 0.1 
mg/l. A commercial control serum was used to verify 
the assay performance.
Patients also received an oral soft tissue examination 
including periodontal measurements of plaque index 
(PI), bleeding on probing (BOP), PPD, and CAL for all 
teeth present. O’Leary PI was measured in four areas 
per tooth (mesiobuccal, midbuccal, distobuccal, and 
midlingual) (20), and the other periodontal parameters 
were registered on six sites by tooth (mesiobuccal, mid-
buccal, distobuccal, mesiolingual, midlingual, and dis-
tolingual).
Study design
All patients with type 1 diabetes from Dr. Peset Hospi-
tal were screened (One hundred thirty-six), and 72 were 
found to match the selection criteria for this pilot study. 
They were told not to change their diet, exercise, or in-
sulin dose unless absolutely necessary and to inform 
investigators if any change occurred. Hs-CRP values at 
the screening time, 3 month previous to the beginning 
of the study, were obtained from the medical records of 
the patients to evaluate changes in this parameter be-
fore the initiation of the investigation. These hs-CRP 
values were obtained in the same center and were made 
by the same laboratory that was used for this clinical 
protocol. The sample was randomized, allowing the 
subjects to self-select a coded number contained in an 
envelope; this number identified the group to which the 
patient was assigned (group 1 or 2). Baseline examina-
tion was performed 3 months after screening and within 
the 30 days prior to the beginning of the periodontal 
treatment. All periodontal measurements were taken 
by only one trained periodontist. Intra-examiner repro-
ducibility was calculated and showed that periodontal 
clinical attachment measurements were in agreement 
within 2 mm more than 90% of the time. This clinician 
was blinded to the treatment applied in each patient and 
care was taken that subjects did not disclose their group 
category (21).
Group 1 had baseline Hs-CRP measured just before the 
beginning of the periodontal treatment. Subjects were 
instructed on the modified Bass brushing technique 
and interproximal cleaning. After that, scaling and root 
planning (SRP) under local anesthesia was performed 
by two trained dental hygienists using ultrasonic de-
vices and manual Gracey curets (Hu-Friedy®, Chicago 
USA). SRP was scheduled in one or two sessions 1 week 
apart according to the periodontal disease severity and 
the number of teeth present. No less than 30 min were 
Number of type 1 diabetics (n) TOTAL (53) Group 1 (24) Group 2 (23) 
Mean age (years) (mean r SD) 35 r 9 38r 10 33r8 
Female 25 (47%) 10(42%) 11 (48%) 
Male 28 (53%) 14 (58%) 12 (52%) 
Diabetes duration (years) (mean r SD) 14 r 7.5 14r 7 13r9 
HbA1c (%) number of diabetics and %    
< 7% 20 (38%) 9 (38%) 8(35%) 
7 - 7.9% 12 (22%) 3(12%) 6(26%) 
t 8% 21 (40%) 12(50%) 9(39%) 
Smoking habits    
nonsmokers 32 15 13 
<15 cig/day 11 4 6 
t15 cig/day 10 5 4 
Baseline periodontal parameters     
Mean PI (%) 60r20 63r21 54r19 
Mean BOP (%) 65r16 65r17 66r17 
Sites with PPD 1-3mm (%) 58 60 58 
Sites with PPD 4-5mm (%) 36 34 36 
Sites with PPD 6mm (%) 6 6 5 
Mean PPD (mm) 3.37 3.4r0.7 3.3r0.6 
Sites with CAL 3mm (%) 51 52 49 
Mean CAL (mm) 2.79 2.9r1.4 2.7r1.2 
Table 1.  Sample Demographics.   
• PI, plaque index; BOP, bleeding on probing; PPD, probing pocket depth; CAL, clinical attachment 
level.
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assigned to each quadrant. Chlorhexidine rinses 0,2% 
were prescribed after SRP (20 ml during 30 s, twice 
daily) and maintained for 12 weeks to the end of the 
clinical protocol. No other rinses or toothpaste was used 
during the study. Individuals were placed on doxycy-
cline 100 mg (b.i.d. for the first day and then one capsule 
per day thereafter) for 15 days.
Group 2 had the same treatment as group 1 with the 
exception of the doxycycline which was not used in this 
group.
Twelve weeks after treatment, blood samples were tak-
en again, and hs-CRP was analyzed. At the same time, 
periodontal parameters were measured again. Perio-
dontal surgical treatment was recommended to patients 
with probing pocket depths ≥6mm. Compliance with 
use of oral hygiene devices, chlorhexidine, and doxycy-
cline was assessed with a personal oral interview with 
the participants. It was classified as good (instructions 
were followed), fair or poor (prescriptions were not fol-
lowed).
At the end of the study, 19 subjects were dropped out. 
Nine patients did not follow post-operative anti-infec-
tious treatment (clorhexidine rinses and doxycycline if 
prescribed), 3 subjects had active acute infections dur-
ing post-treatment period and 7 patients had an inade-
quate baseline laboratory exam (high-sensitivity C-
reactive protein test could not be performed). Finally, 
baseline hs-CRP could be obtained from 53 patients and 
post-treatment hs-CRP was measured in 47 individuals 
(24 patient from group 1 and 23 patients from group 2).
Statistical analysis
First, laboratory and periodontal data were analyzed 
for distribution. Kolmogorov-Smirnov test showed that 
hs-CRP values before and after periodontal treatment 
(primary variables) did not follow a normal distribu-
tion. Consequently, hs-CRP data was expressed as me-
dian with minimum and maximum and non-parametric 
statistics were used to analyze the results. Periodontal 
parameters (secondary variables) followed a normal 
distribution and mean with standard deviation values 
were given. 
Hs-CRP changes after non surgical periodontal treat-
ment were studied by using the Wilcoxon test, and 
differences were considered significant when p<0.05. 
Power analysis was performed. 
Baseline correlations between non-parametric hs-CRP 
values and periodontal measurements were analyzed 
with the Spearman test. Correlations were considered 
statistically significant when p<0.05. Correlation be-
tween hs-CRP and independent variables such as age, 
sex, diabetes duration, diabetes control, diabetes com-
plications and smoking habits was performed with the 
same test. 
Results
Baseline Hs-CRP was obtained from 53 type 1 diabet-
ic subjects who participated in the study and was ex-
pressed in mg/l.  Sample description has been reported 
previously. This data was correlated with periodontal 
clinical parameters on each patient such as percentages 
of BOP sites, mean PPD and mean CAL. No correlation 
was found between hs-CRP and BOP (r-squared=0.12 
and p=0.39), however, significant correlation appeared 
between hs-CRP and mean PPD (r-squared= 0.33 and 
p=0, 01) and between hs-CRP and mean CAL (r=0.29 
and p=0,03). Higher values of hs-CRP were associated 
with higher PPD and more CAL. These results show 
that higher hs-CRP is found as periodontal disease se-
verity increase. Statistical analysis did not show any 
correlation between hs-CRP and other variables such 
as age, sex, diabetes duration, diabetes control, diabetes 
complications and smoking habits which exclude these 
factors as confounders. 
Hs-CRP value at the screening time was compared with 
hs-CRP at baseline, just before periodontal treatment 
was performed 3 months after screening. The goal of 
this analysis was to observe how hs-CRP changed in 
3 months in the absence of dental treatment. Hs-CRP 
could be obtained from the medical records of 17 pa-
tients and it was observed a mean absolute oscillation of 
0.5 mg/l during this time frame.  The minimum change 
experienced was 0%, and the maximum change was 
3.8%. Mean hs-CRP and standard deviation could not 
be calculated because sample had not a parametric dis-
tribution. 
Baseline periodontal characteristics of the sample can 
be observed in table 1. Patients have a moderate to se-
vere periodontal disease (mean PPD=3.37mm and mean 
CAL=2.79mm) with significant BOP (mean BOP=60%) 
and no good plaque control (mean PI=60%). These pa-
tients were divided in two groups. Group 1 (24 subjects) 
were treated with non surgical periodontal treatment 
associated to doxycycline for 15 days. Group 2 (23 in-
dividuals) were treated as group 1 with the exception of 
doxycycline.  Baseline data across all clinical periodon-
tal parameters was almost within the same range and 
statistical analysis did not show any significant differ-
ence between the two groups at baseline visit (p > 0.05). 
Both groups showed very good periodontal response 
to treatment; PI, BOP, PPD, and CAL showed a very 
significant improvement. However, after this successful 
nonsurgical periodontal treatment, hs-CRP levels did 
not change significantly.
Hs-CRP changes after periodontal treatment were an-
alyzed in group 1 and in group 2. Median hs-CRP at 
baseline was 1.27mg/l (min0.16-max7.6) in group 1and 
1.19 (min0.16-max5.4) in group 2. Three months after 
treatment, median hs-CRP was 1.05mg/l (min0.16-
max7.8) and 0.98 (min0.16-max5.4) respectively. These 
Med Oral Patol Oral Cir Bucal. 2012 Jul 1;17 (4):e562-8.                                                                                                                                                        CRP in type 1 diabetes and periodontitis
e566
differences were not statistically significant according 
to Wilcoxon test (Table 2). This sample had a statistical 
power of 86% to detect hs-CRP changes after periodon-
tal treatment ≥0.5mg/l (p<0.05). No difference between 
groups was observed comparing hs-CRP reduction af-
ter periodontal treatment. 
Hs-CRP variations were also studied in the patients with 
the best periodontal response to treatment (Table 3). To 
achieve this goal, patients with the highest BOP and PPD 
showed a post-treatment minimal reduction on hs-CRP 
value that was not statistically significant (p=0.75). 
Patients with diabetes and the higher hs-PRC at baseline 
were selected from groups 1 and 2, and hs-CRP oscil-
lations were analyzed. Sixteen patients with initial hs-
CRP ≥ 2 mg/l were included, 7 from group 1 and 9 from 
group 2. Median hs-CRP was 4.2mg/l (min2-max7.6) 
initially and 4.3 mg/l (min 1.5-max7.8) 3 months after 
periodontal treatment, and these minimal changes were 
Group 
Initial hs-CRP 
(baseline)
Final hs-CRP 
(3 months post-treatment) 
Wilcoxon test 
Median 
(Min-Max)
Median 
(Min-Max)
Group 1 (n=24) 1.27 (0.16-7.6) 1.05 (0.16-7.8) p=0.77* 
Group 2 (n=23) 1.19 (0.16-5.4)  0.98 (0.16-5.4) p=0.98* 
Table 2. hs-CRP values (mg/l) at baseline and 3 months after treatment.  Median (Minimum-Maximum) 
are presented.
* No statistical difference 
Initial hs-CRP 
(baseline)
Final hs-CRP 
(3 months post-treatment) Wilcoxon test 
Median 
(Min-Max)
Median 
(Min-Max)
Patients with t60% BOP 
reduction (n=17) 
1.3 (0.2-5.5) 0.92 (0.2-7.8) P=0.09* 
Patients with t18%  mean 
PPD reduction (n=24) 
1.43 (0.2-7.6)  1.38 (0.2-7.8) P=0.75* 
Patients with hs-CRP 
t2mg/l at baseline (n=16) 4.2 (2-7.6) 4.3 (1.5-7.8) P=0.69* 
Table 3.  hs-CRP values (mg/l) at baseline and 3 months after treatment in the subgroups with the best periodontal 
response to treatment and with the higher hs-CRP at baseline. Median (Minimum-Maximum) are presented.
* No statistical difference 
** BOP, bleeding on probing; PPD, probing pocket depth.
reduction after periodontal treatment were selected 
from group 1 and 2. A total of 17 patients with BOP re-
duction above 60% was obtained; nine of these patients 
came from group 1, and 8 patients came from group 2. 
In this group of patients with the best BOP reduction, 
median hs-CRP was 1.3 mg/l (min0.2-max5.5) initially 
and 0.92 mg/l (0.2min-max7.8) at the re-evaluation. 
Reduction of hs-CRP after periodontal treatment was 
not statistically significant (p=0.09). Another group 
was made with patients with the most significant PPD 
reduction after therapy. For this purpose, 24 patients 
were selected, and these patients had reduced the mean 
baseline PPD to 18% or more. Thirteen of these patients 
were from group 1 and eleven were from group 2. Me-
dian hs-CRP was 1.43 mg/l (min0.2-max7.6) at baseline 
and 1.38 mg/l (min0.2-max7.8) after treatment, which 
not significant (p=0.69). These results suggest that hs-
CRP might not change after periodontal treatment in 
patients with type 1 diabetes, even in the cases with the 
highest initial hs-CRP (Table 3).
Differences between smokers and nonsmokers regard-
ing hs-CRP at baseline and after periodontal treatment 
were not analyzed in this study because the smokers 
group was very small. Only 10 patients from the total 
sample smoked ≥15 cigarettes a day. Thus, statistical 
analysis of this comparison was not possible.
Discussion
Eligible subjects that participate in this study, had 14 
or more natural teeth, of which at least five had a site 
with probing pocket depth (PPD) ≥ 5 mm and clinical 
attachment level (CAL) ≥ 3 mm. We have found in the 
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literatures different criteria to evaluate periodontal dis-
ease severity and a consensus cannot be established. 
Therefore, we studied patients with at least 5 teeth with 
one PPD ≥ 5mm and CAL ≥ 3 mm, to assure that some 
degree of periodontal destruction and periodontal in-
flammation was present in the sample.
This clinical study has found a correlation between ad-
vanced periodontitis and elevated blood hs-CRP levels 
in patients with type 1 diabetes, however, periodontal 
treatment could not reduce significantly hs-CRP values, 
even in the patients with the best response to this treat-
ment. 
Mean PPD and mean CAL is a continuous variable to 
evaluate periodontal disease severity (22), other authors 
have used discontinuous variables classifying this dis-
ease in low threshold periodontitis (mild periodontal 
disease) and high threshold periodontitis (advanced dis-
ease) (23). Mean PPD and mean CAL are a pretty accu-
rate ways of evaluating periodontal disease severity and 
these values were correlated with hs-CRP levels to find 
any relationship. After analyzing correlations, results 
have shown that higher values of hs-CRP are found as 
periodontal disease severity increase. This finding could 
be expected because several reports have indicated how 
periodontal disease acts as any other chronic infec-
tion or inflammatory process in the body. Periodontitis 
produces bacteraemias (24,25) and the host responds 
with  elevated levels of interleukin-6 (IL-6), known to 
induce hepatocytes to produce CRP and other acute-
phase proteins and pro-coagulant mediators (5). Thus, 
it is not surprising that high levels of CRP have been 
observed in peripheral blood samples in patients with 
type 1 diabetes and severe periodontitis. Other authors 
have found the same association in healthy individuals 
(10,11,26,27).
A correlation between mean BOP and hs-CRP was not 
found and this could be explained considering that BOP 
can be produced by periodontitis but also by plaque in-
duced gingivitis and consequently, this is not a good pa-
rameter to evaluate periodontal disease severity. 
High levels of CRP are not recommended in subjects 
with type 1 diabetes because they can increase insu-
lin resistance and they can also exacerbate ongoing in-
flammatory processes in the blood vessels accelerating 
the progression of diabetic complications. It has been 
shown that elevated CRP levels in patients with perio-
dontitis affects inflammation in atherosclerotic lesions, 
increasing the risk for cardiovascular and cerebrovas-
cular events (28,29). High CRP levels (42.1 mg/l) are 
associated with a higher incidence of acute thrombotic 
events including stroke and myocardial infarction (29).
Non surgical periodontal treatment performed in this 
clinical study was very effective in reducing periodon-
tal inflammation and these results has been report previ-
ously (22). This periodontal improvement was followed 
by a reduction on hs-CRP values but not to a significant 
level.
The sample studied had a statistical power of 86% to 
detect hs-CRP changes after periodontal treatment 
≥0.5mg/l (p<0.05) which could be considered clinically 
significant. The hs-CRP reduction after periodontal 
treatment detected in this study could be statistically 
significant increasing the sample size, but this 0.2mg/l 
reduction may not be clinically significant.
Even in the patients with the best response to periodon-
tal treatment reduction was not statistically significant. 
Neither diabetic patient with the higher initial hs-CRP 
show any change in this parameter after periodontal 
treatment. Long-term clinical studies evaluating the ef-
fect of periodontal treatment on CRP values are scarce, 
especially when patients with diabetes are considered. 
Some treatment studies on healthy individuals have 
shown a reduction on CRP levels after periodontal 
treatment (12). In two studies from D’Aiuto et al. (30) 
a standard and an intense periodontal treatment was 
given to different treatment groups. Both treatment mo-
dalities reduced blood CRP levels but the meta-analysis 
comparing the two treatment protocols (standard versus 
intensive treatment) failed to show a significant benefit 
of the intensive treatment, however a trend towards in-
tensive treatment was noted. There are also reports in 
the literature on patients with type 2 diabetes that found 
no clear effect of periodontal treatment on CRP (16,17) 
and same results can be found in healthy patients with 
periodontal disease (13,14). 
We have to consider that CRP is a non-specific marker 
of the acute-phase response, and according to that, peri-
odontal disease but also other potential stimuli such as 
unknown chronic infections or inflammatory condi-
tions may produce mild CRP increases. Some authors 
have shown that smoking, obesity or trauma may affect 
CRP values (31) and we also have to keep in mind that 
vascular alteration in diabetic patients are inflammatory 
processes that could increase blood inflammatory me-
diators. On the other hand, it has been reported that a 
hyper-reactive immune system is associated with peri-
odontal disease. According to this, it could be speculat-
ed that certain diabetic individuals would have a more 
hyper-reactive immune system, which would produce 
more periodontal destruction, but also a higher blood 
concentration of inflammatory mediators as a response 
to the damage of the circulatory system that diabetes 
mellitus produces. Thus, periodontal treatment would 
reduce periodontal inflammation significantly but not 
blood inflammatory substances such as hs-CRP. 
It is concluded that there was an association between 
advanced periodontitis and elevated blood hs-CRP lev-
els in patients with type 1 diabetes. Non-surgical peri-
odontal treatment could not reduce hs-CRP values to a 
significant level. It can be speculated that periodontal 
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disease increases production of pro-inflammatory me-
diators such as CRP in subjects with type 1 diabetes 
but other producing sources of these pro-inflammatory 
substances should be identified in these patients. These 
high CRP levels could be involved in the development 
of diabetic complications and periodontal disease pro-
gression and reduction of these values should be a medi-
cal goal in these patients. More studies increasing sam-
ple size are needed to clarify the benefits of periodontal 
treatment in patients with type 1 diabetes and to relate 
inflammatory mediators with periodontal progression 
and diabetic complications.
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